Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN)

CAPS Rating: 3 out of 5

A biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases.

Recs

0
Player Avatar j3nzsrfs (< 20) Submitted: 11/25/2006 10:29:17 PM : Outperform Start Price: $8.35 ENZN Score: -24.32

New cancer treatment

Report this Post Reply

Featured Broker Partners


Advertisement